anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a process for preparing excrement antigens of native mites, which preparation process comprises the steps of antigen extraction wherein domestic mite excrements of minimal purity 95 percent by volume adhering during the breeding to the surface of the breeding container walls serve as a source of pure excrements. In the course of mite breeding, there is only used 1 to 5 mg of a growth medium per 1 cme2 of the breeding area, the growth medium never forms a continuous layer and is added successively. The mite breeding lasts from its starting at the most 8 weeks, whereby turning the breeding containers with the cultures of mites during breeding at regular intervals causes uniform adhesion of the excrements to all the walls of the breeding container. After coverage of the breeding containers with a continuous layer of the mite excrements, the residual growth medium, which does not serve as a source of the mite excrement antigens, is removed, and subsequently live mites adhering to the walls are removed after foregone cold paralysis. Owing to this, there are obtained: (i) mite excrements with minimum purity 95 percent by volume adhering to the walls of the breeding containers; (ii) live mites of minimum purity 95 percent by volume; and (iii) a residual growth medium containing less than 50 percent by volume live mites. The extraction of antigens from the mite excrements adhering to the breeding contained walls with minimum purity 95 percent by volume is carried out by water agitation immediately within the space of the breeding container after finish of the mite breeding to thereby directly obtaining a protein extract from excrements. The protein extract is then subjected to centrifuging to obtain a supernatant. After lyophilization of the supernatant, a sample of a fingerprint analysis by means of a two-dimensional proteomic analysis and/or western blot analysis is used for validation of the composition and integrity of the thus prepared antigens from mite excrements.
The success of lung transplantation (LTx) is significantly hindered by the lack of sufficient number of available donors. Many potential donor lungs cannot be utilized in clinical transplantation because donors have chronic viral infections such as hepatitis C (HCV) infection. This study will test the possibility of safely transplanting lungs from HCV positive donors. Donor lungs will be subjected to Normothermic Ex vivo Lung Perfusion (EVLP) for 6 hours for organ assessment and reduction of viral load prior to transplantation. After transplantation, recipients will be carefully monitored for HCV infection and if infection occurs, they will be promptly treated with highly effective antiviral therapy using newly approved DAAs. The aim of the study is to show that transplantation of lungs from HCV positive donors is safe in the era of DAAs. The hypothesis is that the rate of HCV transmission to recipients will be lower than previously described due to EVLP pre-treatment and any HCV transmission that does occur will be readily treatable and curable. If successful, the knowledge from this study can have a large impact to patients with end stage organ diseases by providing a large novel source of donors for lung and potentially other organ transplantations.
PROBLEM TO BE SOLVED: To obtain the subject new compound useful as a therapeutic agent for acute promyelogenic leukemia and thrombosis, by stabilizing instable 9-cis- retinoic acid with its medicinal activity left intact. SOLUTION: This new compound is expressed by formula I (ring containing Y and Z is a carbon ring residue or heteroatom-contg. ring residue having at least one double bond, and the double bond and heteroatom may be present in Y or Z), e.g. 1-(1,3,3-trimethyl-1-cyclohexen-2-yl)-2-[2-(1-carboxy-2-methyl-1- buten-4-yl)phenyl]ethylene. The compound of formula I is obtained by a process wherein a compound of formula II (X is a halogen, etc.; R<1> is an alkyl) is reacted with a compound of formula III to form a compound of formula IV which is then reduced into the corresponding alcohol, which is, in turn, oxidized into the corresponding aldehyde, which is then subjected to trans-selective condensation reaction with a compound of formula V (R<2> is the same as R<1> ) followed by hydrolysis.
Patch 2, Patch 4 and Patch 6 applied on peristomal skin. Patch 1- Patch 6 applied on healthy abdominal skin Measurements of skin at three locations of each patch: Center and under adhesive.
The present invention relates to a method for preparing compound micron pseudostellaria root sour milk for reducing blood sugar and supplementing calcium. Raw material such as soymilk liquor, xylitol, intestinal tract beneficial bacteria, etc. are added into micron pseudostellaria root powder, micron ophiopogon root powder, micron spirulina powder, micron nacre powder and micron amino acid chromium through high-technology airflow superfine grinding, and processed and combined into the sour milk. The sour milk has the obvious function of reducing blood sugar and also has the effects of supplementing calcium, improving osteoporosis, allaying fatigue, enhancing immunity, tranquilizing, improving eyesight, etc. The sour milk can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc., and simultaneously, the sour milk has the functions of beautifying faces, keeping youthfulness, tranquilizing and reducing blood sugar because the micron nacre powder extolled as an oriental youthfulness keeping treasure and the amino acid chromium extolled as a blood sugar reducing factor are added. Therefore, the present invention is a favorable method for preparing health-care sour milk food for health care and longevity, and the sour milk has Chinese characteristics and is especially designed for middle-aged diabetics and old diabetics all over the world.
BACKGROUND AND AIMS: Infection is a serious complication in patients with cirrhosis. Mucosal-associated invariant T (MAIT) cells are involved in the immune defense against infections and known to be impaired in several chronic conditions, including cirrhosis. Here, we evaluated if MAIT cell levels in peripheral blood are associated with risk of bacterial infections in patients with cirrhosis.
METHODS: Patients with cirrhosis seen at the Karolinska University Hospital, Stockholm, Sweden, between 2016 and 2019 were included. Levels of MAIT cells in peripheral blood were determined using flow cytometry. Baseline and follow-up data after at least two years of follow-up were collected by chart review for the primary outcome (bacterial infection) and secondary outcomes (decompensation and death). Competing risk and Cox regression were performed.
RESULTS: We included 106 patients with cirrhosis. The median MAIT cells fraction in the circulation was 0.8% in cirrhosis compared to 6.1% in healthy controls. In contrast to our hypothesis, we found an association in the adjusted analysis between relatively preserved MAIT cell levels, and a slightly higher risk to develop bacterial infections (adjusted subdistribution hazard ratio (aSHR) 1.15 (95%CI = 1.01-1.31). However, MAIT cell levels were not associated with the risk of hepatic decompensation (aSHR 1.19 (95%CI = 0.91-1.56)) nor with death (adjusted hazard ratio 1.10 (95%CI = 0.97-1.22)).
CONCLUSIONS: Relatively preserved MAIT cell levels in blood of patients with cirrhosis were associated with a somewhat higher risk of bacterial infections. The clinical relevance of this might not be strong. MAIT cells might however be an interesting biomarker to explore in future studies.
Administered in monotherapy or in combination with other targeted agents or immunotherapies, chemotherapies, or radiation. Combination treatment plans may include a two-week monotherapy lead-in, followed by a combination treatment regimen. Each ACT study intervention must have an established RP2D determined in a prior clinical trial. Participants undergo a Pre-Treatment Biopsy, plus an On-Treatment Biopsy after two weeks on first dose of study drug(s) and prior to starting Cycle 2, regardless of regimen. Participants continue to receive study agent(s) after the On-Treatment Biopsy, according to the biopsy results and the results of ongoing safety and clinical assessments. Treatment cycles repeat every 21 to 28 days in the absence of disease progression or unacceptable toxicity. Cycles are determined based on the study agent(s). Upon disease progression, participants are given the option to undergo an additional biopsy.
The study will include 20 patients who are diagnosed with CNV and were submitted for intravitreal injection of avastin. Patients with uncontrolled glaucoma, any ocular operation two months prior to the injection, ocular inflammatory disease, systemic hypertension treated with more than one medication, myocardial infarct, congestive heart disease will not be included in the study. After the patient will approve to participate in the study and will fall in with the inclusion and exclusion criteria, the patient will sign a written consent statement (enclosed).

Medical history and ophthalmic examination will be written in the study file. The patients will undergo the full-field ERG test using the ISCEV Protocol. Since the ERG is a non invasive test the patient will be admitted on the same day for intravitreal avastin in the designated eye. After one month the patient will undergo identical ERG protocol in addition to the standard follow-up examinations protocol for intravitreal avastin injection (1 day, 1 week, 1 month). The other eye will serve as control group.
Store in a refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. 

SPINRAZA should be protected from light and kept in the original carton until time of use. 

If no refrigeration is available, SPINRAZA may be stored in its original carton, protected from light at or below 30oC (86oF) for up to 14 days. 

Prior to administration, unopened vials of SPINRAZA can be removed from and returned to the refrigerator, if necessary. If removed from the original carton, the total combined time out of refrigeration should not exceed 30 hours at a temperature that does not exceed 25oC (77oF).
PCT No. PCT/US92/00442 Sec. 371 Date Jul. 1, 1993 Sec. 102(e) Date Jul. 1, 1993 PCT Filed Jan. 17, 1992 PCT Pub. No. WO92/13844 PCT Pub. Date Aug. 20, 1992.The present invention is novel compounds which are 4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidine substituted 1,2,4- and 1,3,4-thiadiazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and particularly rheumatoid arthritis, osteoarthritis, other inflammatory conditions, psoriasis, allergic diseases, asthma, inflammatory bowel disease, GI ulcers, cardiovascular conditions, including ischemic heart disease and atherosclerosis, and ischemia-induced cell damage, particularly brain damage caused by stroke. They can also be used topically for treating acne, sunburn, psoriasis, and eczema. Also included are leukotriene mediated pulmonary, gastrointestinal, inflammatory, dermatological, and cardiovascular conditions. The disclosed compounds also have potential utility as antioxidants. The preferred use is in treating inflammatory conditions. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.
The invention relates to the technical field of medicines. The invention provides a tadalafil-polyglutamic acid amorphous composition, a preparation method and application thereof. The tadalafil-polyglutamic acid amorphous composition has the drug loading rate of 75%, and overcomes the defect of low drug loading rate of the traditional solid dispersion. At the same time, the high T of polyglutamic acid is benefited from  g  The physical stability of the tadalafil-polyglutamic acid amorphous composition is also greatly improved. In addition, the tadalafil-polyglutamic acid amorphous composition also significantly improves the water solubility of tadalafil. More importantly, different solubilization profiles can be obtained for tadalafil-polyglutamic acid amorphous compositions with different mass ratios, thereby providing tadalafil with different drug release profilesThe design of the non-preparation provides various choices, and lays a foundation for meeting different clinical requirements of tadalafil.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to compounds of the formula (I)   where A means optionally substituted phenyl under condition that groups -CH(R 3 )N(R 2 )M-R 1  and -OD are in 1,2-position with respect to with each other in carbon ring atoms and carbon ring atom locating in ortho-position to -OD-binding group (therefore, at 3-position with respect to -CHR 3 NR 2 -binding group) is unsubstituted; B means pyridyl or pyridazinyl; R 1  is located in ring B in 1,4-position with respect to -CHR 3 NR 2 - binding group and presented as determined in claim 1 of the invention claim; R 2  means C 1-6 -alkyl; R 3  means hydrogen atom; D means hydrogen atom, optionally substituted 5-7-membered carbocyclic ring containing one double bond or D means group of the formula (CH 2 ) n CH(R 4 )C(R 5 )=C(R 6 )R 7  where R 4  means hydrogen atom, methyl or ethyl group; R 5  means hydrogen atom, methyl group, bromine, chlorine or fluorine atom; R 6  means hydrogen atom, C 1-4 -alkyl; R 7  means hydrogen atom, C 1-4 -alkyl, bromine, chlorine or fluorine atom; n = 0 or 1. Invention relates also to their pharmaceutically acceptable salts or esters hydrolyzed in vivo. Compounds are antagonists of effect of prostaglandin E-type enhancing pain. Also, invention relates to pharmaceutical composition used for pain relief based on the above described compounds and to method of pain relief using the above described compounds. Also, invention proposes method of synthesis of compounds of the formula (I) based on the above described compounds and their pharmaceutically acceptable salts or esters hydrolyzed in vivo and intermediate compounds synthesized in the process of their synthesis. EFFECT: improved methods of synthesis and preparing, valuable medicinal properties. 13 cl, 6 tbl, 67 ex
Congestive Heart Failure, Cardiac Effects and Drug Interactions:

Itraconazole Capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of Itraconazole Capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions, ADVERSE REACTIONS: Post-marketing Experience, and CLINICAL PHARMACOLOGY: Special Populations for more information.)

Drug Interactions: Coadministration of the following drugs are contraindicated with Itraconazole Capsules: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor. In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. See PRECAUTIONS: Drug Interactions Section for specific examples. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. See CONTRAINDICATIONS and WARNINGS Sections, and PRECAUTIONS: Drug Interactions Section for specific examples.
In the process for the preparation of recognins, optionally provided with a carrier, normal or diseased tissue is extracted with a neutral buffer with repeated disintegration of the tissue. By this means, protein fractions are dissolved or solubilised. Extraction is then carried out. The fraction having a pK range of 1 to 4 is separated off from the resulting extract of the dissolved or solubilised proteins. This is achieved by adding the extract of the dissolved or solubilised proteins to a chromatographic column and eluting with increasingly acidic solvents. A product is isolated therefrom having a molecular weight of 3,000 to 25,000. The isolation is carried out by filtering the eluate in order to obtain a fraction which contains recognin. The recognin is separated therefrom by thin-layer gel chromatography. The recognin obtained is optionally mixed with a carrier for the purpose of forming a complex compound. This process enables the preparation of recognins which are used for diagnosis and for control of malignant tissue.
PURPOSE:To obtain a foamable aerosol composition which is less inflammable and excellent in low-temp. foamability and has no fear of container troubles at high temps., such as explosion, by incorporating a combination of a gas soluble under pressure and n-butane as a propellant into a base liquid. CONSTITUTION:A base liquid (A) comprising an aqueous solution of active components of, e.g. a hair treatment, a hair fixative, or a shaving preparation, a surfactant (e.g. a polyoxyethylene sorbitan fatty acid ester), etc., is mixed with a gas soluble under pressure (B) (e.g. carbon dioxide) and n-butane (C) to produce the title composition. Due to the use of n-butane as a propellant component, not only the composition has improved low-temp. foamability, but also the aerosol container is inhibited from exploding when heated to a high temp. The weight ratio of the propellant ingredients (B) to (C) is preferably at least 20/80.
Measuring the clinical attachment loss using a periodontal probe is the benchmark by which attachment loss is diagnosed in periodontal disease. The accuracy and reproducibility of the probing measurements is an essential part of diagnosis, treatment planning and assessment of the treatment outcome. There are inherent errors associated with probing that have been identified in the literature. These relate to the operator technique, the probe used and the state of inflammation of the periodontal pocket/crevice.

The aim of this study is to compare the reproducibility of probing measurements using a probe tip with millimeter markings up to 15mm in the Florida probe ® handpiece. This tip will be used to allow conventional clinical measurements to be recorded at the same time as the electronic recordings on the Florida probe ®. The examiner would take the manual probe measurement and be blind to the electronic reading taken. The sites under question will have a second measurement recorded to allow assessment of the repeatability of the recordings. Therefore, from 2 probing passes 4 measurements would be obtained 2 manual and 2 electronic readings.
Participants must take 4 capsules per day, with water. The product should be taken with the last meal of the day.
Autistic spectrum disorder (ASD) is a neurodevelopmental disability characterised by the impairment of social interaction and communication ability. The alarming increase in its prevalence in children urged researchers to obtain a better understanding of the causes of this disease. Genetic factors are considered to be crucial, as ASD has a tendency to run in families. In recent years, with technological advances, the importance of structural variations (SVs) in ASD began to emerge. Most of these studies, however, focus on the Caucasian population. As a populated ethnicity, ASD shall be a significant health issue in China. This systematic review aims to summarise current case-control studies of SVs associated with ASD in the Chinese population. A list of genes identified in the nine included studies is provided. It also reveals that similar research focusing on other genetic backgrounds is demanded to manifest the disease etiology in different ethnic groups, and assist the development of accurate ethnic-oriented genetic diagnosis.
An initial dose of deferasirox FCT 7 mg/kg/day was used for 3 months (12 weeks), then was adjusted according to the serum ferritin (SF) level. Deferasirox was interrupted when the study-defined target SF ≤ 100 μg/L was achieved. Deferasirox was to be reinitiated when SF ≥ 300 μg/L, according to deferasirox label.
PURPOSE OF REVIEW: Universal and targeted screening of newborns for congenital cytomegalovirus (CMV) infection is increasing globally. Questions remain concerning the management of infants who have been identified with congenital CMV infection, especially those with "minimally symptomatic" or clinically inapparent infection. Our objective is to discuss current management of CMV-infected neonates with a focus on less affected infants with or without sensorineural hearing loss (SNHL).
RECENT FINDINGS: Valganciclovir is being prescribed increasingly in neonates with congenital CMV infection for improvement in hearing outcomes through 2 years of age. Treatment initiated in the first month of age is recommended for clinically apparent disease. A recent study showed hearing improvement at 18-22 months of age when therapy was initiated at age 1-3 months in infants with clinically inapparent CMV infection and isolated SNHL.
SUMMARY: Antiviral therapy with either ganciclovir or valganciclovir has shown moderate benefit in prevention of hearing deterioration among infants with clinically apparent CMV infection or isolated SNHL. Sustainability of benefit beyond 2 years of age remains unknown. At present, infants with clinically inapparent CMV infection (normal complete evaluation including hearing) should not receive antiviral therapy. All CMV-infected infants require close audiological and neurodevelopmental follow-up.
The invention relates to a method of quickly preparing the model of an animal such as a dog with portal hypertension. A polyurethane-tetrahydrofuran-carbon tetrachloride solution is prepared by mixing polyurethane, tetrahydrofuran and carbon tetrachloride in a glass container, sealing, standing at room temperature and shaking slightly. When in use, the polyurethane-tetrahydrofuran-carbon tetrachloride solution is sucked by a glass syringe and directly and slowly injected into the portal vein of the conventionally-anesthetized dog in a puncturing way by adopting the B-type ultrasound guidance or performing the minilaparotomy. The experimental animal subjected to the minilaparotomy is raised conventionally. By preparing the polyurethane-tetrahydrofuran-carbon tetrachloride solution and directly and slowly injecting the polyurethane-tetrahydrofuran-carbon tetrachloride solution into the portal vein of the conventionally-anesthetized dog in a puncturing way by adopting the B-type ultrasound guidance or performing the minilaparotomy, the model of the animal with portal hypertension can be built instantaneously. The method has the advantages of high speed, little damage and high success rate, is easy to operate and is suitable for studying the portal hypertension for various purposes.